COO

Business Context and Reporting Period

Company: The Cooper Companies, Inc. (COO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended October 31, 2024
Business Overview: A global medical device company operating through two segments: CooperVision (contact lenses and myopia management) and CooperSurgical (fertility and women's health products and services). The company serves markets in the Americas, EMEA, and Asia Pacific.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 8% to $3.895 billion. CooperVision sales grew 8% (driven by silicone hydrogel lenses), while CooperSurgical sales grew 10% (driven by the Cook Medical acquisition and fertility consumables). Growth was partially offset by unfavorable foreign exchange impacts of approximately $24.1 million combined.
• Profitability: Operating income rose 32% to $705.7 million. CooperSurgical operating income surged 635% to $118.3 million, primarily due to a $45.0 million termination fee paid in the prior year related to a Cook Medical asset purchase agreement that did not recur in 2024.
• Expenses: Selling, General, and Administrative (SGA) expenses increased 2% overall. CooperVision SGA rose due to increased selling activities, while CooperSurgical SGA decreased due to the absence of the prior year's termination fee. Research and Development (R&D) expenses increased 13% to $155.1 million.
• Acquisitions: The company spent $343.4 million on acquisitions in fiscal 2024, including obp Surgical ($100 million) and a fertility company specializing in sperm separation devices ($33.5 million).
• Tax Rate: The effective tax rate increased to 32.6% from 28.7%, driven by changes in the geographic mix of earnings and a UK statutory tax rate increase.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management remains optimistic about long-term prospects in contact lens and healthcare markets but cites risks from global economic conditions, inflation, and supply chain disruptions.
• Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to IT general controls for U.S. operations within the CooperSurgical segment. This was due to the implementation of new ERP systems, insufficient personnel, and inadequate training. Consequently, the independent auditor (KPMG) issued an adverse opinion on the effectiveness of internal controls, though the financial statements themselves received an unqualified opinion.
• Dividends: The Board decided in December 2023 to end the declaration of the semiannual dividend.
• Capital Structure: In May 2024, the company entered a new $2.3 billion Revolving Credit Facility, using proceeds to repay prior term loans. As of October 31, 2024, $1.049 billion was outstanding on the revolver and $1.5 billion on the 2021 Term Loan.
• Risks: Key risks include foreign currency fluctuations, regulatory changes (FDA, EU MDR/IVDR), cybersecurity threats, and reliance on sole suppliers for raw materials (e.g., silicone hydrogel).

Investor Verification Checklist

• Internal Control Remediation: Verify the progress of remediation efforts for the material weakness in CooperSurgical's IT general controls and the timeline for restoring an effective control environment.
• Acquisition Integration: Monitor the integration and financial performance of recent acquisitions (obp Surgical, Cook Medical assets) to ensure anticipated synergies are realized.
• Regulatory Compliance: Track compliance with evolving regulations, specifically the FDA's new rules on Laboratory Developed Tests (LDTs) and EU Medical Device Regulations (MDR/IVDR), which could impact CooperSurgical's genetic testing and device portfolios.
• Debt Servicing: Assess the impact of rising interest rates on the company's variable-rate debt obligations and future interest expense.
• Foreign Exchange Exposure: Evaluate the company's hedging strategies given that over half of net sales are derived from outside the U.S. and the significant impact of currency fluctuations on reported results.